Shareholder Votes

BuzzFeed, Inc. shareholders approved Appointment of the Company’s Independent Registered Public Accounting Firm at the 2026-06-02 meeting.

“Proposal 2: Appointment of the Company’s Independent Registered Public Accounting Firm The stockholders ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows: For Against Abstain 90,981,426 313,813 21,545”

BuzzFeed, Inc. shareholders approved Election of Directors at the 2026-06-02 meeting.

“Proposal 1: Election of Directors Janet Rollé and Adam Rothstein were re-elected to the Company’s board of directors as Class II directors, to each serve a three-year term expiring at the 2029 annual meeting of stockholders and until such director’s successor is duly elected and qualified. The results of the election were as follows: Name of Nominee For Withheld Broker Non-Votes Janet Rollé 73,277,359 990,015 17,049,410 Adam Rothstein 73,584,572 682,802 17,049,410”

Figma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-06-02 meeting.

“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm. Votes For Votes Against Abstentions Broker Non-Votes 1,534,306,843 1,044,457 303,772 0”

Figma, Inc. shareholders approved Election of eight directors to serve until 2027 annual meeting at the 2026-06-02 meeting.

“Proposal 1: Election of Directors. Nominee Votes For Votes Withheld Broker Non-Votes Dylan Field 1,451,125,084 13,350,079 71,179,909 Kelly A. Kramer 1,461,710,737 2,764,426 71,179,909 John Lilly 1,441,654,786 22,820,377 71,179,909 William R. McDermott 1,446,140,185 18,334,978 71,179,909 Andrew Reed 1,451,713,525 12,761,638 71,179,909 Danny Rimer 1,441,267,392 23,207,771 71,179,909 Lynn Vojvodich Radakovich 1,451,702,370 12,772,793 71,179,909 Luis von Ahn 1,462,482,960 1,992,203 71,179,909”

Royalty Pharma plc shareholders approved Authorization to allot shares without pre-emptive rights at the 2026-06-04 meeting.

“Proposal 10. To authorize the Board of Directors to allot shares without rights of pre-emption:”

Royalty Pharma plc shareholders approved Authorization to allot shares at the 2026-06-04 meeting.

“Proposal 9. To authorize the Board of Directors to allot shares:”

Royalty Pharma plc shareholders approved Approval of share purchase agreements and counterparties at the 2026-06-04 meeting.

“Proposal 8. To approve the terms of the agreements and counterparties pursuant to which the Company may purchase its Class A ordinary shares:”

Royalty Pharma plc shareholders approved Authorization for Board to determine U.K. statutory auditor remuneration at the 2026-06-04 meeting.

“Proposal 7. To authorize the Board of Directors to determine the remuneration of the Company’s U.K. statutory auditor:”

Royalty Pharma plc shareholders approved Re-appointment of Ernst & Young as U.K. statutory auditor at the 2026-06-04 meeting.

“Proposal 6. To re-appoint Ernst & Young as the Company’s U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders:”

Royalty Pharma plc shareholders approved Advisory vote on U.K. directors' remuneration report at the 2026-06-04 meeting.

“Proposal 5. To approve, on a non-binding advisory basis, the Company’s U.K. directors’ remuneration report in the U.K. Annual Report and Accounts:”

Royalty Pharma plc shareholders approved Approval of U.K. statutory accounts and reports at the 2026-06-04 meeting.

“Proposal 4. To approve receipt of the Company’s U.K. statutory accounts together with the Company’s U.K. statutory reports, including the directors’ report, the strategic report, the directors’ remuneration report and the auditors’ report for the fiscal year ended December 31, 2025 ("U.K. Annual Report and Accounts") :”

Royalty Pharma plc shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2026-06-04 meeting.

“Proposal 3. To ratify the appointment of Ernst & Young LLP, as the Company’s independent registered public accounting firm:”

Royalty Pharma plc shareholders approved Advisory vote on executive compensation at the 2026-06-04 meeting.

“Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers:”

Royalty Pharma plc shareholders approved Election of nine directors at the 2026-06-04 meeting.

“Proposal 1. To elect nine directors, each by separate ordinary resolutions, to the Company’s Board of Directors to serve until the 2027 Annual General Meeting of Shareholders:”

MFA FINANCIAL, INC. shareholders approved Advisory (non-binding) resolution to approve the Company's executive compensation at the 2026-06-03 meeting.

“For Against Abstentions Broker Non-Votes 48,100,115 2,135,819 671,107 23,418,611”

MFA FINANCIAL, INC. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“For Against Abstentions 73,275,772 690,827 359,053”

MFA FINANCIAL, INC. shareholders approved Election of two Class I directors to serve on the Board until the 2029 Annual Meeting of Stockholders at the 2026-06-03 meeting.

“Laurie S. Goodman 48,746,159 1,930,702 230,180 23,418,611 Richard C. Wald 48,370,172 2,287,586 249,283 23,418,611”

Oruka Therapeutics, Inc. shareholders approved Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis at the 2026-06-02 meeting.

“Proposal 3: Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis. The Company’s stockholders approved, by non-binding advisory vote, the compensation of our named executive officers as disclosed in the Proxy Statement. The tabulation of votes on this matter was as follows: Shares voted for: 43,033,967 Shares voted against: 875,114 Shares abstaining 73,091 There were 1,267,194 broker non-votes for this proposal.”

Oruka Therapeutics, Inc. shareholders approved Ratification of Independent Auditor Appointment at the 2026-06-02 meeting.

“Proposal 2: Ratification of Independent Auditor Appointment. The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. Shares voted for: 45,206,297 Shares voted against: 39,637 Shares abstaining 3,432 There were no broker non-votes for this proposal.”

Oruka Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-02 meeting.

“Proposal 1: Election of Directors. The Company’s stockholders elected each of the two Class II directors proposed by the Company for election, to serve until the 2029 annual meeting of stockholders, and until their successors are elected and have qualified. The tabulation of votes on this matter was as follows: Director Nominee Shares Voted For Shares Withheld Lawrence Klein 43,918,579 63,593 Chris Martin 43,936,173 45,999 There were 1,267,194 broker non-votes for this proposal.”

EMCOR Group, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent auditors for 2026 at the 2026-06-04 meeting.

“Proposal 3. The proposal for stockholders to ratify the appointment of Ernst & Young LLP as the Company’s independent auditors for 2026 was approved based upon the following votes: Shares For 36,270,830 Shares Against 3,248,493 Shares Abstaining 17,910”

EMCOR Group, Inc. shareholders approved To consider a non-binding advisory resolution approving named executive officer compensation at the 2026-06-04 meeting.

“Proposal 2. The proposal for stockholders to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers was approved based upon the following votes: Shares For 32,437,835 Shares Against 4,870,814 Shares Abstaining 52,900 Broker Non-Votes 2,175,684”

EMCOR Group, Inc. shareholders approved To elect nine directors identified in the proxy statement on Schedule 14A related to the 2026 Annual Meeting of Stockholders of the Company to serve until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified at the 2026-06-04 meeting.

“Proposal 1. The nominees for director were elected based upon the following votes: Nominee Shares For Shares Against Shares Abstaining Broker Non-Votes John W. Altmeyer 34,863,327 2,478,850 19,372 2,175,684”

MasterBrand, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2026 at the 2026-06-04 meeting.

“Proposal 3 – Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026. Votes For Votes Against Abstentions Votes Cast 112,161,309 360,108 594,994 The shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal year 2026.”

MasterBrand, Inc. shareholders approved Advisory vote on the Company's 2025 Named Executive Officer compensation at the 2026-06-04 meeting.

“Proposal 2 – Advisory vote on the Company’s 2025 Named Executive Officer compensation. Votes For Votes Against Abstentions Broker Non-Votes Votes Cast 98,960,374 1,931,187 704,626 11,520,224 The shareholders approved the Company’s 2025 Named Executive Officer compensation.”

MasterBrand, Inc. shareholders approved Election of three director nominees to serve three-year terms at the 2026-06-04 meeting.

“Proposal 1 – Election of three director nominees to serve three-year terms. Nominee Votes For Votes Against Abstentions Broker Non-Votes Ann Fritz Hackett 99,471,548 1,596,328 528,311 11,520,224 R. David Banyard, Jr. 100,608,637 467,406 520,144 11,520,224 Philip Fracassa 100,765,328 263,363 567,496 11,520,224 The shareholders elected each of the nominees as directors.”

OnKure Therapeutics, Inc. shareholders approved Approval of the Amended and Restated 2024 Equity Incentive Plan at the 2026-06-03 meeting.

“For Against Abstentions Broker Non-Votes 16,431,575 3,490,523 1,895 5,466,123”

OnKure Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm at the 2026-06-03 meeting.

“For Against Abstentions Broker Non-Votes 25,329,425 60,370 321 -”

OnKure Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-03 meeting.

“R. Michael Carruthers 19,776,757 147,236 5,466,123 Valerie M. Jansen, M.D., Ph.D. 17,796,919 2,127,074 5,466,123 Edward T. Mathers 19,855,396 68,597 5,466,123”

Beachbody Company, Inc. shareholders approved Advisory approval of the Company’s executive compensation at the 2026-06-02 meeting.

“The advisory approval was obtained by the votes indicated.”

Beachbody Company, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

“The selection was ratified by the votes indicated.”

Beachbody Company, Inc. shareholders approved Election of nine nominees to serve on the Board of Directors for a one-year term to expire at the Company’s 2027 annual meeting of stockholders at the 2026-06-02 meeting.

“The following nine directors were elected by the votes indicated.”

BAB, INC. shareholders approved Ratification of CBIZ CPAs P.C. as independent auditors for fiscal year ending November 30, 2026 at the 2026-06-03 meeting.

“2. To act upon a proposal to ratify the appointment of CBIZ CPAs P.C. as independent auditors of the Company for the fiscal year ending November 30, 2026. Votes For Against Abstain Broker Non-Votes 4,404,741 98,332 128,167 -”

BAB, INC. shareholders approved Election of four directors to serve until 2027 annual meeting at the 2026-06-03 meeting.

“1. To elect four Directors to serve for a one-year term expiring when their successors are elected and qualified at the annual meeting in 2027. Votes For Votes Withheld Broker Non-Votes 01 Michael Evans 2,968,915 668,582 993,743 02 Steven Feldman 2,941,969 695,528 993,743 03 James Lentz 2,941,969 695,528 993,743 04 Geraldine Conn 2,941,379 696,118 993,743”

CV Sciences, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-02 meeting.

“Proposal 3 - Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth below: FOR AGAINST ABSTAIN BROKER NON-VOTE 102,384,289 12,488,529 1,361,966 -”

CV Sciences, Inc. shareholders rejected Reverse Stock Split at the 2026-06-02 meeting.

“Proposal 2 - Reverse Stock Split The Company's stockholders did not approve the Company's proposal to amend its Certificate of Incorporation, as amended to effect, at the discretion of the Board of Directors, a reverse stock split of all outstanding shares of common stock at a ratio of not less than 1-for-10 and not greater than 1-for-800, such ratio to be determined by the Board of Directors at any time before May 30, 2029, without further approval or authorization from its stockholders, as set forth below: FOR AGAINST ABSTAIN BROKER NON-VOTE 48,496,747 59,628,926 8,109,111 -”

CV Sciences, Inc. shareholders approved Election of Directors at the 2026-06-02 meeting.

“Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject to prior death, resignation or removal, as set forth below: NAME FOR AGAINST ABSTAIN BROKER NON-VOTE Dr. Jamie Corroon 39,505,495 3,183,772 1,078,738 72,466,779 Joseph Dowling 37,674,977 4,813,319 1,279,709 72,466,779 Bill McCorkle 22,671,092 3,928,542 17,168,371 72,466,779”

Grindr Inc. shareholders approved Advisory vote regarding the frequency of the future advisory votes on named executive officers’ compensation at the 2026-06-02 meeting.

“Proposal Five: Advisory vote regarding the frequency of the future advisory votes on named executive officers’ compensation The result of the advisory proposal regarding the frequency of the future advisory votes on the compensation of the Company’s named executive officers (the “Say-on-Frequency Proposal”) was as follows:”

Grindr Inc. shareholders approved Advisory vote on compensation of the Company’s named executive officers at the 2026-06-02 meeting.

“Proposal Four: Advisory vote on compensation of the Company’s named executive officers The result of the advisory vote on compensation of the Company’s named executive officers was as follows:”

Grindr Inc. shareholders approved Amendment and Restatement of the Grindr Inc. 2022 Equity Incentive Plan at the 2026-06-02 meeting.

“Proposal Three: Amendment and Restatement of the Grindr Inc. 2022 Equity Incentive Plan The Company’s stockholders approved the amendment and restatement of the Grindr Inc. 2022 Equity Incentive Plan, as previously amended and restated in 2024.”

Grindr Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-02 meeting.

“Proposal Two: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Grindr Inc. shareholders approved Election of Directors at the 2026-06-02 meeting.

“Proposal One: Election of Directors The Company’s stockholders elected the eight persons listed below to serve on the Board until the Company’s 2027 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal.”

iHeartMedia, Inc. shareholders approved Approval of the second amendment to the iHeartMedia, Inc. 2021 Long-Term Incentive Award Plan at the 2026-06-04 meeting.

“Proposal 4 - Approval of the second amendment to the iHeartMedia, Inc. 2021 Long-Term Incentive Award Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 94,485,819 4,225,053 751,838 8,957,386”

iHeartMedia, Inc. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers at the 2026-06-04 meeting.

“Proposal 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 83,318,864 15,393,581 750,265 8,957,386”

iHeartMedia, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

“Proposal 2 - Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 105,605,578 2,064,752 749,766 0”

iHeartMedia, Inc. shareholders approved Election of eight directors to the Company’s Board of Directors, each for a one-year term ending at the 2027 Annual Meeting at the 2026-06-04 meeting.

“Proposal 1 - Election of Robert W. Pittman, James A. Rasulo, Richard J. Bressler, Samuel E. Englebardt, Robert Millard, Cheryl Mills, Graciela Monteagudo and Kamakshi Sivaramakrishnan to the Company’s Board of Directors, each for a one-year term ending at the Company’s 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Robert W. Pittman 98,198,349 1,264,361 8,957,386 James A. Rasulo 90,172,403 9,290,307 8,957,386 Richard J. Bressler 98,272,353 1,190,357 8,957,386 Samuel E. Englebardt 92,222,506 7,240,204 8,957,386 Robert Millard 92,249,273 7,213,437 8,957,386 Cheryl Mills 91,757,728 7,704,982 8,957,386 Graciela Monteagudo 98,223,356 1,239,354 8,957,386 Kamakshi Sivaramakrishnan 98,231,980 1,230,730 8,957,386”

GLOBUS MEDICAL INC shareholders approved Approval, on a non-binding, advisory basis, of the 2025 compensation of the Company’s named executive officers.

“The Company’s stockholders approved, on a non-binding, advisory basis the 2025 compensation of the Company’s named executive officers, as described in the Proxy Statement.”

GLOBUS MEDICAL INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-12-31 meeting.

“The Company’s stockholders approved the ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

GLOBUS MEDICAL INC shareholders approved Approval of 2021 Equity Incentive Plan Amendment.

“The Company’s stockholders approved the 2021 Equity Incentive Plan Amendment.”

GLOBUS MEDICAL INC shareholders approved Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders.

“Each of the director nominees listed below were elected by the Company’s stockholders at the Annual Meeting to serve a three-year term on the Board.”